Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

Chronic Diabetic Foot Ulcers Clinical Trial

Official title:
A Randomised, Double-blind, Placebo-controlled Study to Determine the Efficacy of Soluble Beta-1,3/1,6-glucan in Chronic Foot Ulcers in Diabetes

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether the application of soluble beta-glucan (SBG) onto diabetic foot ulcers improves the healing of the ulcers.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00632008
Study type	Interventional
Source	Biotec Pharmacon ASA
Contact
Status	Completed
Phase	Phase 3
Start date	March 2007
Completion date	October 2009

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04457752` - Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)	Phase 4
Terminated	`NCT02571738` - Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers	Phase 3
Recruiting	`NCT00366132` - Safety & Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Diabetic Foot Ulcers	Phase 2
Terminated	`NCT05276401` - Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer	Phase 2
Completed	`NCT03282981` - Beta Adrenergic Antagonist for the Healing of Chronic DFU	Phase 3
Completed	`NCT02098447` - Pilot Study on Auricular Vagus Nerve Stimulation Effects in Chronic Diabetic Wounds	N/A
Withdrawn	`NCT00954343` - Shockwave Treatment of Diabetic Foot Ulcer: Step I	N/A
Recruiting	`NCT04962139` - Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers	Phase 3